FreshPatents.com Logo
stats FreshPatents Stats
1 views for this patent on FreshPatents.com
2010: 1 views
Updated: July 25 2014
newTOP 200 Companies filing patents this week


    Free Services  

  • MONITOR KEYWORDS
  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • ORGANIZER
  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • ARCHIVE
  • View the last few months of your Keyword emails.

  • COMPANY DIRECTORY
  • Patents sorted by company.

Follow us on Twitter
twitter icon@FreshPatents

Antiviral agent

last patentdownload pdfimage previewnext patent


Title: Antiviral agent.
Abstract: An object of the present invention is to provide a viral disease control agent which has a mechanism of action different from conventional one as a substitute for existing viral disease control methods and is used in more practical and safer manners. The present invention utilizes a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein. ...


USPTO Applicaton #: #20100216981 - Class: 536 245 (USPTO) - 08/26/10 - Class 536 
Organic Compounds -- Part Of The Class 532-570 Series > Azo Compounds Containing Formaldehyde Reaction Product As The Coupling Component >Carbohydrates Or Derivatives >Nitrogen Containing >Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) >Nucleic Acid Expression Inhibitors

view organizer monitor keywords


The Patent Description & Claims data below is from USPTO Patent Application 20100216981, Antiviral agent.

last patentpdficondownload pdfimage previewnext patent

US 20100216980 A1 20100826 1 44 1 2892 DNA Leucosporidium antarcticum 1 atgctcttcc tccccgtcct cctcctcctc cttcccggcg tcactgcctt cctcaaccca 60 gttaccaacc gcgcgaccaa cgccatctcc tcgactcaat acctctctaa cgcctatatc 120 ctcgaattgg acctctccac ccccggcctc gtcaaacggg atagcacgcc cgactctatc 180 ctagaggacg tactcacgtc cgtaggccgc aacggtatca agtaccaact ccgccaccgc 240 tttatctccc cgactctgtt ccacggcgct tcgatcactg tcccccctgg aatctcccgc 300 tcccaaatcg cctctctccg cggtatcaaa cgcgtctggc ccgttcgaaa gttctcccga 360 cccagcgcag tagtggacgc cgatggagga ggaagcgggt tctcagggtc gcctatcaag 420 gcggcgctca tgggggtgaa agagctcggg aagcgcgcga acgcttatgc tggagatacg 480 tttggaccgc atgtcatgac gggggttaat gagacgcatg aggcggggtt gttgggagct 540 gggattaaga ttggggtgct ggacactggt gttgattatt tgaacccgat tctgggaggc 600 tgctttggac ctgggtgcca tatgtcgttt gggtacgact tggttggcga tgattacgat 660 ggagataacg ctcctgtgcc ggatgtggat ccttttgcga gctgcgatcc tcatggaact 720 cacgttacgg gaatcattgg agcgctcccg aatgcgtttg gatttactgg cgtcgcaccc 780 gccgctactc tgggccacta ccgagtattt ggctgcactg gcttcgtcgg agaagatatc 840 attctcgctg gactcatgcg aggagtcgag gacaactgca acgtcttgac cctctctctc 900 ggaggtccag gagggtgggt caagggcacg ccggcgtcca tccttatcga ccagatcgaa 960 gcgcaaggca ttctcgtcac cgtcgccact ggcaactcgg gagctgaggg catgttcttc 1020 tccgagtctc ccgcctcgac gatcaacggc ctttccatcg catccacgga cgttaccgac 1080 ctcatcgcct acaacgccac cgtctcaggc caacctgcga tcccttacct ctccgccacg 1140 cccctcaacg tcgtcgccaa cagcttccgc gtccacttca cctctaccga ccccaacaac 1200 cccgtcgacg cctgctctcc tcttccggct ggagcgcccg acttcgccaa ctatgttacg 1260 gtcgttcagc gtgggacttg tacgttcgtt accaagtacc agaacgttct caatgctgga 1320 ggaaagatcg tattgttgta caactcggag ggagctggga acctccctta cctcacgccc 1380 aacggtgtcg gcatcgacgc cgttgcaggt cttcgtcgtt ccgacggact caagcttctc 1440 tcgtactatc agaatgccaa caagcgtctc actctgcgct tccccaaggg caagatcgtc 1500 gcaggcttga ccgataccat caccggcgga ctcatctcgg gttactcgac gtttggtccg 1560 acgaatgacc tctacggtca gcctaccctc tctgcccctg gtggcaacat cctttcgacc 1620 ttccctctct ccgagggagg agtggcggtc atcagtggga cgagcatgtc gtgccccttt 1680 gtcgctggat ctgcggcggt cctcatggcc gctcgcgctt cggagaacct cacgccgctt 1740 gagatcagga gtctccttac taccactgcg aagcttacgc cggtctcgct cttgggatcg 1800 acgcctttgg tgagcgtgat tcgtcaagga ggaggactcg ttcaggttgc caaggcgctc 1860 gcggccaaga cgctaatctc tcctcacgag ctcctgctca acgacactgc gaacgcgaac 1920 tacgtccaga ctatcaagat caagaacacc aactcgtggg cgatgaagta caccttctcc 1980 tcggccgtcg cccaaggact cggaactttc gacgcttcgg gcgatatcct ccctaccctc 2040 gacccagtcg ccgtctctgg cgcacaggct accgtcgcgt tcaacactcg gatcctcagc 2100 gtcgcgcccg gcgcgacggg gtccgtcgtg gcgactatca cgccgccggt tcttcccgta 2160 gcggacgctg cgaggttccc tatcttctct gggtggatca gggtgaatgg gcaaggcgcg 2220 agggatagca gtaggaacga ggcgtacact gtcccgtact ttgggcttgc ggcgaagatg 2280 atcgatatgc aagtcctcga caccaccgag accatttacg gtccgggcta cgcctacccc 2340 ttcgtgatcg acgacgcgat tggagacatc caatccacca caacgtcgta ctccaggaac 2400 ctcgggccca ccgtcttcgc tcgctttgcc actggaaccc ttcactacag cctcgatctc 2460 gtcctagccg acatcgcctt tacccccacc taccccaact cctcccccgc cactcgtttc 2520 gtcaagcgct ccctcacgca gcacacctct gccgcttcgc acctcgccaa gcgccgcgtc 2580 tccatcgcca ctatcaaccc caaagccacc ctcgtcgccg atcgacagct ccactcggac 2640 gtccctatcg agggcaacat cttcacccaa ccctttactg gaagggatta cctcgtcgac 2700 gcagccccga cgggatccac cgatcgtacc gtcactttta acgggcagta cgccgagaac 2760 ggcctcgtga ggacggctgt gacggggact tcgtaccgct tcctccttcg ggcgttgaag 2820 atctcgggag acgcgatgta cgaggatcag tatgagagct ggctctcgct accgttctcg 2880 ttccgtgcgt ag 2892 2 963 PRT Leucosporidium antarcticum 2 Met Leu Phe Leu Pro Val Leu Leu Leu Leu Leu Pro Gly Val Thr Ala 1 5 10 15 Phe Leu Asn Pro Val Thr Asn Arg Ala Thr Asn Ala Ile Ser Ser Thr 20 25 30 Gln Tyr Leu Ser Asn Ala Tyr Ile Leu Glu Leu Asp Leu Ser Thr Pro 35 40 45 Gly Leu Val Lys Arg Asp Ser Thr Pro Asp Ser Ile Leu Glu Asp Val 50 55 60 Leu Thr Ser Val Gly Arg Asn Gly Ile Lys Tyr Gln Leu Arg His Arg 65 70 75 80 Phe Ile Ser Pro Thr Leu Phe His Gly Ala Ser Ile Thr Val Pro Pro 85 90 95 Gly Ile Ser Arg Ser Gln Ile Ala Ser Leu Arg Gly Ile Lys Arg Val 100 105 110 Trp Pro Val Arg Lys Phe Ser Arg Pro Ser Ala Val Val Asp Ala Asp 115 120 125 Gly Gly Gly Ser Gly Phe Ser Gly Ser Pro Ile Lys Ala Ala Leu Met 130 135 140 Gly Val Lys Glu Leu Gly Lys Arg Ala Asn Ala Tyr Ala Gly Asp Thr 145 150 155 160 Phe Gly Pro His Val Met Thr Gly Val Asn Glu Thr His Glu Ala Gly 165 170 175 Leu Leu Gly Ala Gly Ile Lys Ile Gly Val Leu Asp Thr Gly Val Asp 180 185 190 Tyr Leu Asn Pro Ile Leu Gly Gly Cys Phe Gly Pro Gly Cys His Met 195 200 205 Ser Phe Gly Tyr Asp Leu Val Gly Asp Asp Tyr Asp Gly Asp Asn Ala 210 215 220 Pro Val Pro Asp Val Asp Pro Phe Ala Ser Cys Asp Pro His Gly Thr 225 230 235 240 His Val Thr Gly Ile Ile Gly Ala Leu Pro Asn Ala Phe Gly Phe Thr 245 250 255 Gly Val Ala Pro Ala Ala Thr Leu Gly His Tyr Arg Val Phe Gly Cys 260 265 270 Thr Gly Phe Val Gly Glu Asp Ile Ile Leu Ala Gly Leu Met Arg Gly 275 280 285 Val Glu Asp Asn Cys Asn Val Leu Thr Leu Ser Leu Gly Gly Pro Gly 290 295 300 Gly Trp Val Lys Gly Thr Pro Ala Ser Ile Leu Ile Asp Gln Ile Glu 305 310 315 320 Ala Gln Gly Ile Leu Val Thr Val Ala Thr Gly Asn Ser Gly Ala Glu 325 330 335 Gly Met Phe Phe Ser Glu Ser Pro Ala Ser Thr Ile Asn Gly Leu Ser 340 345 350 Ile Ala Ser Thr Asp Val Thr Asp Leu Ile Ala Tyr Asn Ala Thr Val 355 360 365 Ser Gly Gln Pro Ala Ile Pro Tyr Leu Ser Ala Thr Pro Leu Asn Val 370 375 380 Val Ala Asn Ser Phe Arg Val His Phe Thr Ser Thr Asp Pro Asn Asn 385 390 395 400 Pro Val Asp Ala Cys Ser Pro Leu Pro Ala Gly Ala Pro Asp Phe Ala 405 410 415 Asn Tyr Val Thr Val Val Gln Arg Gly Thr Cys Thr Phe Val Thr Lys 420 425 430 Tyr Gln Asn Val Leu Asn Ala Gly Gly Lys Ile Val Leu Leu Tyr Asn 435 440 445 Ser Glu Gly Ala Gly Asn Leu Pro Tyr Leu Thr Pro Asn Gly Val Gly 450 455 460 Ile Asp Ala Val Ala Gly Leu Arg Arg Ser Asp Gly Leu Lys Leu Leu 465 470 475 480 Ser Tyr Tyr Gln Asn Ala Asn Lys Arg Leu Thr Leu Arg Phe Pro Lys 485 490 495 Gly Lys Ile Val Ala Gly Leu Thr Asp Thr Ile Thr Gly Gly Leu Ile 500 505 510 Ser Gly Tyr Ser Thr Phe Gly Pro Thr Asn Asp Leu Tyr Gly Gln Pro 515 520 525 Thr Leu Ser Ala Pro Gly Gly Asn Ile Leu Ser Thr Phe Pro Leu Ser 530 535 540 Glu Gly Gly Val Ala Val Ile Ser Gly Thr Ser Met Ser Cys Pro Phe 545 550 555 560 Val Ala Gly Ser Ala Ala Val Leu Met Ala Ala Arg Ala Ser Glu Asn 565 570 575 Leu Thr Pro Leu Glu Ile Arg Ser Leu Leu Thr Thr Thr Ala Lys Leu 580 585 590 Thr Pro Val Ser Leu Leu Gly Ser Thr Pro Leu Val Ser Val Ile Arg 595 600 605 Gln Gly Gly Gly Leu Val Gln Val Ala Lys Ala Leu Ala Ala Lys Thr 610 615 620 Leu Ile Ser Pro His Glu Leu Leu Leu Asn Asp Thr Ala Asn Ala Asn 625 630 635 640 Tyr Val Gln Thr Ile Lys Ile Lys Asn Thr Asn Ser Trp Ala Met Lys 645 650 655 Tyr Thr Phe Ser Ser Ala Val Ala Gln Gly Leu Gly Thr Phe Asp Ala 660 665 670 Ser Gly Asp Ile Leu Pro Thr Leu Asp Pro Val Ala Val Ser Gly Ala 675 680 685 Gln Ala Thr Val Ala Phe Asn Thr Arg Ile Leu Ser Val Ala Pro Gly 690 695 700 Ala Thr Gly Ser Val Val Ala Thr Ile Thr Pro Pro Val Leu Pro Val 705 710 715 720 Ala Asp Ala Ala Arg Phe Pro Ile Phe Ser Gly Trp Ile Arg Val Asn 725 730 735 Gly Gln Gly Ala Arg Asp Ser Ser Arg Asn Glu Ala Tyr Thr Val Pro 740 745 750 Tyr Phe Gly Leu Ala Ala Lys Met Ile Asp Met Gln Val Leu Asp Thr 755 760 765 Thr Glu Thr Ile Tyr Gly Pro Gly Tyr Ala Tyr Pro Phe Val Ile Asp 770 775 780 Asp Ala Ile Gly Asp Ile Gln Ser Thr Thr Thr Ser Tyr Ser Arg Asn 785 790 795 800 Leu Gly Pro Thr Val Phe Ala Arg Phe Ala Thr Gly Thr Leu His Tyr 805 810 815 Ser Leu Asp Leu Val Leu Ala Asp Ile Ala Phe Thr Pro Thr Tyr Pro 820 825 830 Asn Ser Ser Pro Ala Thr Arg Phe Val Lys Arg Ser Leu Thr Gln His 835 840 845 Thr Ser Ala Ala Ser His Leu Ala Lys Arg Arg Val Ser Ile Ala Thr 850 855 860 Ile Asn Pro Lys Ala Thr Leu Val Ala Asp Arg Gln Leu His Ser Asp 865 870 875 880 Val Pro Ile Glu Gly Asn Ile Phe Thr Gln Pro Phe Thr Gly Arg Asp 885 890 895 Tyr Leu Val Asp Ala Ala Pro Thr Gly Ser Thr Asp Arg Thr Val Thr 900 905 910 Phe Asn Gly Gln Tyr Ala Glu Asn Gly Leu Val Arg Thr Ala Val Thr 915 920 925 Gly Thr Ser Tyr Arg Phe Leu Leu Arg Ala Leu Lys Ile Ser Gly Asp 930 935 940 Ala Met Tyr Glu Asp Gln Tyr Glu Ser Trp Leu Ser Leu Pro Phe Ser 945 950 955 960 Phe Arg Ala 3 1739 DNA Leucosporidium antarcticum 3 gcttgtctca agattaagcc atgcatgtct aagtttaagc aataaacggt gaaactgcga 60 atggctcatt aaatcagtca tagtttattt gatggtaccc tactacatgg ataactgtgg 120 taattctaga gctaatacat gccgaaaaat ctcgacttct ggaagagatg tatttattag 180 atccaaaacc agtggccttc gggtctcctt ggtgaatcat gataactgct cgaatcgcat 240 ggccttgcgc cggcgatgct tcattcaaat atctgcccta tcaactttcg atggtaggat 300 agaggcctac catggtgatg acgggtaacg gggaataagg gttcgattcc ggagagaggg 360 cctgagaaac ggccctcagg tctaaggaca cgcagcaggc gcgcaaatta tcccctggca 420 acactttgcc gagatagtga caataaataa caatgcaggg ctcttacggg tcttgcaatt 480 ggaatgagta caatttaaat cccttaacga ggatccattg gagggcaagt ctggtgccag 540 cagccgcggt aattccagct ccaatagcgt atattaaagt tgttgccgtt aaaaagctcg 600 tagtcgaact tcggtccttg ttggtcggtc cgccttcttg gtgtgtactt actcaacgag 660 gacttacctc ctggtgagct gcaatgtcct ttactgggtg ttgtagggaa ccaggacgtt 720 tactttgaaa aattagagtg ttcaaagcag gcctacgccc gaatacatta gcatggaata 780 tagaatagga cgcgcgttcc cattttgttg gtttctgaga tcgccgtaat gattaatagg 840 gatagttggg ggcattcgta ttccgtcgtc agaggtgaaa ttcttggatt gccggaagac 900 gaactattgc gaaagcattt gccaaggatg ttttcattga tcaagaacga aggaaggggg 960 atcgaaaacg atcagatacc gttgttgtct cttctgtaaa ctatgccaat tggggattag 1020 ctcaggattt ttaatgactg agttagcacc cgaagagaaa tctttaaatg aggttcgggg 1080 gggagtatgg tcgcaaggct gaaacttaaa ggaattgacg gaagggcacc accaggtgtg 1140 gagcctgcgg cttaatttga ctcaacacgg ggaaactcac caggtccaga cacaataagg 1200 attgacagat tgatagctct ttcttgatct tgtggttggt ggtgcatggc cgttcttagt 1260 tggtggagtg atttgtctgg ttaattccga taacgaacga gaccttaacc tgctaaatag 1320 accagccggc tttggctggc tgctgtcttc ttagagggac tatcagcgtt tagctgatgg 1380 aagtttgagg caataacagg tctgtgatgc ccttagatgt tctgggccgc acgcgcgcta 1440 cactgacaga gccagcgagt ctaccacctt ggccggaagg cctgggtaat cttgtgaaac 1500 tctgtcgtga tggggataga acattgcaat tattgttctt caacgaggaa tacctagtaa 1560 gcgtgagtca tcagctcgcg ttgattacgt ccctgccctt tgtacacacc gcccgtcgct 1620 actaccgatt gaatggctta gtgaggcctc cagattggct attaggatct cgcgagagaa 1680 cttgactgct gaaaagttgt acgaacttgg tcatttagag gaagtaaaag tcgtaacaa 1739 4 608 DNA Leucosporidium antarcticum 4 tggggaagga tcattagcga atttagcgtt tctcttaaca gagcgcgacc ctccactttc 60 ttaactctgt gaactttttt ggtcaagcat ggcgttttct cgattgactt ttattagaaa 120 gttgggacta cacattttgc ttgacggctc attttaaaca ctagtacaag tatgtaacga 180 aatatcgaaa tataaaaaaa ctttcaacaa cggatctctt ggctctcgca tcgatgaaga 240 acgcagcgaa atgtgataag taatgtgaat tgcagaattc agtgaatcat cgaatctttg 300 aacgcacctt gcgctcccta gtattctggg gagcatgtct gtttgagtgt catgaactct 360 tcaactctat cgtttcttgt taagcgatta gaagtttgga ttttgaatgt tgctagtcct 420 tttacgggac tttagctcgt tcgtaataca ttagcctttc taattccgaa cttcggattg 480 actcagtgta atagactatt cgctgaggac actagtaata gtggccgata ttcaacataa 540 gaaaagcttc aaacctttgt agtcaatttt agattagacc tcagatcagg caggattaac 600 ccgccgaa 608 5 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 5 ccgaattcgt cgacaacaga gtttgatcct 30 6 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 6 cccgggatcc aagcttacgg ctaccttgtt 30 7 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 7 aacctggttg atcctgccag t 21 8 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 8 tgatccttct gcaggttcac ctac 24 9 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 9 tccgtaggtg aacctgcgga aggatcatta 30 10 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 10 cttttcctcc gcttcttgat atgcttaagt 30 11 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 11 tcacagaagt atgccaagcg a 21 12 19 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 12 agggtcaaga cgttgcagt 19 13 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 13 atgcgaagtc agaagcagga tc 22 14 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 14 gcagccaaat acctggaagc ac 22 15 20 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 15 tttttttttt tttttttttt 20 16 26 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 16 atgctcttcc tccccgtcct cctcct 26 17 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 17 tcagcgaacg aacgaggaga aggt 24 18 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 18 aagcagtggt atcaacgcag agtacgcggg 30 19 27 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 19 tttttttttt tttttttttt tttttvn 27 20 57 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 20 aagcagtggt atcaacgcag agtacttttt tttttttttt tttttttttt tttttvn 57 21 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 21 ctaatacgac tcactatagg gc 22 22 29 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 22 accagtgtcc agcaccccaa tcttaatcc 29 23 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 23 tcatcagtgg gacgagcatg tcgt 24 24 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 24 gcgggggccg acaataaaaa c 21 25 34 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 25 tttttttttt tttttttttt ttttttgagg tggc 34 26 29 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 26 caagccctag gctacgcacg gaacgagaa 29 27 32 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 27 ctgccgaatt cttcctcaac ccagttacca ac 32 28 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 28 tactattgcc agcattgctg c 21 29 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 29 gactggttcc aattgacaag c 21 30 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic primer 30 gcaaatggca ttctgacatc c 21 31 1321 DNA Leucosporidium antarcticum 31 cgcagctccc actcactcgt gcttccaggt atttggctgc actggcttcg tcggagaaga 60 tatcgttcgt cctctctcca gtcccggcta gcgatcctgc ttctgacttc gcatctccct 120 ctcagattct cgctggactc atgcgaggag tcgaggacaa ctgcaacgtc ttgaccctct 180 ctctcggagg tccaggaggg tgggtcaagg gcacgccggc gtccatcctt atcgaccaga 240 tcgaagcgca aggcattctc gtcaccgtcg ccactggcaa ctcgggagct gagggtgagc 300 tcctcgctac ttgcgcgtcg agaccagtac taacaggggc gtggacgcag gcatgttctt 360 ctccgagtct cccgcctcga cgatcaacgg cctttccatc gcatccacgt ccgtctctcc 420 cttccttcgc acgccactcg ctcacactct ctcgcaggga cgttaccgac ctcatcgcct 480 acaacgccac cgtctcaggc caacctgcga tcccttacct ctccgccacg cccctcaacg 540 tcgtcgccaa cagcttccgc gtccacttca cctctaccga ccccaacaac cccgtcgacg 600 cctgctctcc tcttccggct ggaacgcccg acctcgccaa ctatgttacg gtcgttcagc 660 gtgggacttg tacgttcgtt accaagtacc agaacgttct caatgctgga gggtgcgtcg 720 gctcttctct cccgactgga ttgggcggag actgaccttc tgagcagaaa gatcgtattg 780 ttgtacaact cggagggagc tgggaacctc ccttacctca cgcccaacgg tgtcggcatc 840 gacgccgttg caggtcttcg tcgttccgac ggactcaagg ttcgtctacg ctcttcggtg 900 ctgaggccct tctctgatct cgctccgaca gcttctctcg tactatcaga atgccaacaa 960 gcgtctcact ctgcgcttcc ccaagggcaa gatcgtcgca ggcttgaccg acaccatcac 1020 cggcggactc atctcgttcg ttcctctccg cctccctcgc tggccgatga gctgacgcgg 1080 tctttgcagg agttactcga cgtttggtcc gacgaatgac ctctacggtc agcctaccct 1140 ctctgcccct ggtggcaaca tcctttcgac cttccctctc tccgagggag gagtggcggt 1200 catcagtggg acgagcatgt cgtgcccctt tgtcggttcg tccttctcct cgttcgttcg 1260 ctgagcgtcg actgatcttg cacgatcgca gctggatctg cggcggtcct catggccgct 1320 c 1321 32 177 DNA Leucosporidium antarcticum 32 atgctcttcc tccccgtcct cctcctcctc cttcccggcg tcactgcctt cctcaaccca 60 gttaccaacc gcgcgaccaa cgccatctcc tcgactcaat acctctctaa cgcctatatc 120 ctcgaattgg acctctccac ccccggcctc gtcaaacggg atagcacgcc cgactct 177 33 153 DNA Leucosporidium antarcticum 33 atcctagagg acgtactcac gtccgtaggc cgcaacggta tcaagtacca actccgccac 60 cgctttatct ccccgactct gttccacggc gcttcgatca ctgtcccccc tggaatctcc 120 cgctcccaaa tcgcctctct ccgcggtatc aaa 153 34 184 DNA Leucosporidium antarcticum 34 cgcagtagtg gacgccgatg gaggaggagc gggttctcag ggtcgcctat caaggcggcg 60 ctcatggggg tgaaagagct cgggaagcgc gcgaacgctt atgctggaga tacgtttgga 120 ccgcatgtca tgacgggggt taatgagacg catgaggcgg ggttgttggg agctgggatt 180 aagg 184 35 95 DNA Leucosporidium antarcticum 35 ctgctttgga cctgggtgcc atatgtcgtt tgggtacgac ttggttggcg atgattacga 60 tggagataac gctcctgtgc cggatgtgga tcctt 95 36 22 DNA Leucosporidium antarcticum 36 ttgcgagctg cgatcctcat gg 22 37 90 DNA Leucosporidium antarcticum 37 aactcacgtt acgggaatca ttagagcgct cccgaatgcg tttggattta ctggcgtcgc 60 acccgccgct actctgggcc actaccgagt 90 38 265 DNA Leucosporidium antarcticum 38 atttggctgc actggcttcg tcggagaaga tatcgttcgt cctctctcca gtcccggcta 60 gcgatcctgc ttctgacttc gcatctccct ctcagattct cgctggactc atgcgaggag 120 tcgaggacaa ctgcaacgtc ttgaccctct ctctcggagg tccaggaggg tgggtcaagg 180 gcacgccggc gtccatcctt atcgaccaga tcgaagcgca aggcattctc gtcaccgtcg 240 ccactggcaa ctcgggagct gaggg 265 39 58 DNA Leucosporidium antarcticum 39 catgttcttc tccgagtctc ccgcctcgac gatcaacggc ctttccatcg catccacg 58 40 254 DNA Leucosporidium antarcticum 40 gacgttaccg acctcatcgc ctacaacgcc accgtctcag gccaacctgc gatcccttac 60 ctctccgcca cgcccctcaa cgtcgtcgcc aacagcttcc gcgtccactt cacctctacc 120 gaccccaaca accccgtcga cgcctgctct cctcttccgg ctggaacgcc cgacctcgcc 180 aactatgtta cggtcgttca gcgtgggact tgtacgttcg ttaccaagta ccagaacgtt 240 ctcaatgctg gagg 254 41 112 DNA Leucosporidium antarcticum 41 aaagatcgta ttgttgtaca actcggaggg agctgggaac ctcccttacc tcacgcccaa 60 cggtgtcggc atcgacgccg ttgcaggtct tcgtcgttcc gacggactca ag 112 42 105 DNA Leucosporidium antarcticum 42 cttctctcgt actatcagaa tgccaacaag cgtctcactc tgcgcttccc caagggcaag 60 atcgtcgcag gcttgaccga caccatcacc ggcggactca tctcg 105 43 174 DNA Leucosporidium antarcticum 43 agttactcga cgtttggtcc gacgaatgac ctctacggtc agcctaccct ctctgcccct 60 ggtggcaaca tcctttcgac cttccctctc tccgagggag gagtggcggt catcagtggg 120 acgagcatgt cgtgcccctt tgtcggttcg tccttctcct cgttcgttcg ctga 174 44 2687 DNA Leucosporidium antarcticum 44 tcacagaagt atgccaagcg aggggggggg gtctgctagc gcgaatcgag aaaacacaaa 60 agaacctccc gacttggcgt tgcttctgct cttctccttc tcccaaccgc cgacaataaa 120 aactataaca cacacacacc ccatctcgac gcctgcagac ttcacgactc tcctcacgct 180 ctttaccgcc ccacgggtcc cacccacgag ccacgatgct cttcctcccc gtcctcctcc 240 tcctccttcc cggcgtcact gccttcctca acccagttac caaccgcgcg accaacgcca 300 tctcctcgac tcaatacctc tctaacgcct atatcctcga attggacctc tccacccccg 360 gcctcgtcaa acgggatagc acgcccgact ctgtgcgtcc cgcgttcctc cctcgctgtc 420 gaagacgagc taacaatgac gtggtagatc ctagaggacg tactcacgtc cgtaggccgc 480 aacggtatca agtaccaact ccgccaccgc tttatctccc cgactctgtt ccacggcgct 540 tcgatcactg tcccccctgg aatctcccgc tcccaaatcg cctctctccg cggtatcaaa 600 gtccgtccct ctctctcccc tactccctcc gtgctaaccc tgcacgcaac agcgcgtctg 660 gcccgttcga agttctcccg acccagcgca gtagtggacg ccgatggagg aggagcgggt 720 tctcagggtc gcctatcaag gcggcgctca tgggggtgaa agagctcggg aagcgcgcga 780 acgcttatgc tggagatacg tttggaccgc atgtcatgac gggggttaat gagacgcatg 840 aggcggggtt gttgggagct gggattaagg tgtgttttcg tctttgtttg ggggaggggg 900 gagggaggag ctgattaatg ggtgcagatt ggggtgctgg acactggtga gaagcggttt 960 ggagggagga gaggatggag ctgatgagtg tgcaggtgtt gattatttga acccgattct 1020 gggaggctgc tttggacctg ggtgccatat gtcgtttggg tacgacttgg ttggcgatga 1080 ttacgatgga gataacgctc ctgtgccgga tgtggatcct tgtgcgtcct tccctccgcg 1140 atgggctgga atctgagctg acggcgttgt tgatcagttg cgagctgcga tcctcatggt 1200 tcgtctcgct ttccgctcct ctgatgcgct cgctgatgca cttggcaata ggaactcacg 1260 ttacgggaat cattagagcg ctcccgaatg cgtttggatt tactggcgtc gcacccgccg 1320 ctactctggg ccactaccga gtgcgctccc tctatccgtt cttcctcgca gctcccactc 1380 actcgtgctt ccaggtattt ggctgcactg gcttcgtcgg agaagatatc gttcgtcctc 1440 tctccagtcc cggctagcga tcctgcttct gacttcgcat ctccctctca gattctcgct 1500 ggactcatgc gaggagtcga ggacaactgc aacgtcttga ccctctctct cggaggtcca 1560 ggagggtggg tcaagggcac gccggcgtcc atccttatcg accagatcga agcgcaaggc 1620 attctcgtca ccgtcgccac tggcaactcg ggagctgagg gtgagctcct cgctacttgc 1680 gcgtcgagac cagtactaac aggggcgtgg acgcaggcat gttcttctcc gagtctcccg 1740 cctcgacgat caacggcctt tccatcgcat ccacgtccgt ctctcccttc cttcgcacgc 1800 cactcgctca cactctctcg cagggacgtt accgacctca tcgcctacaa cgccaccgtc 1860 tcaggccaac ctgcgatccc ttacctctcc gccacgcccc tcaacgtcgt cgccaacagc 1920 ttccgcgtcc acttcacctc taccgacccc aacaaccccg tcgacgcctg ctctcctctt 1980 ccggctggaa cgcccgacct cgccaactat gttacggtcg ttcagcgtgg gacttgtacg 2040 ttcgttacca agtaccagaa cgttctcaat gctggagggt gcgtcggctc ttctctcccg 2100 actggattgg gcggagactg accttctgag cagaaagatc gtattgttgt acaactcgga 2160 gggagctggg aacctccctt acctcacgcc caacggtgtc ggcatcgacg ccgttgcagg 2220 tcttcgtcgt tccgacggac tcaaggttcg tctacgctct tcggtgctga ggcccttctc 2280 tgatctcgct ccgacagctt ctctcgtact atcagaatgc caacaagcgt ctcactctgc 2340 gcttccccaa gggcaagatc gtcgcaggct tgaccgacac catcaccggc ggactcatct 2400 cgttcgttcc tctccgcctc cctcgctggc cgatgagctg acgcggtctt tgcaggagtt 2460 actcgacgtt tggtccgacg aatgacctct acggtcagcc taccctctct gcccctggtg 2520 gcaacatcct ttcgaccttc cctctctccg agggaggagt ggcggtcatc agtgggacga 2580 gcatgtcgtg cccctttgtc ggttcgtcct tctcctcgtt cgttcgctga gcgtcgactg 2640 atcttgcacg atcgcagctg gatctgcggc ggtcctcatg gccgctc 2687 US 20100216981 A1 20100826 US 12450150 20080319 12 JP 2007-077970 20070323 20060101 A
C
07 H 21 04 F I 20100826 US B H
20060101 A
C
07 C 49 553 L I 20100826 US B H
20060101 A
C
07 C 49 543 L I 20100826 US B H
20060101 A
C
07 C 49 537 L I 20100826 US B H
US 536 245 568327 568377 568379 ANTIVIRAL AGENT Sano Shinsuke
Chigasaki JP
omitted JP
Fukagawa Takako
Odawara JP
omitted JP
Yamada Hirokazu
Ichihara JP
omitted JP
Masuta Chikara
Sapporo JP
omitted JP
Shimura Hanako
Sapporo JP
omitted JP
OLIFF & BERRIDGE, PLC
P.O. BOX 320850 ALEXANDRIA VA 22320-4850 US
Nippon Soda Co., Ltd. 03
Tokyo JP
Hokkaido University 03
Sapporo-shi JP
WO PCT/JP2008/000655 00 20080319 20090914

An object of the present invention is to provide a viral disease control agent which has a mechanism of action different from conventional one as a substitute for existing viral disease control methods and is used in more practical and safer manners. The present invention utilizes a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.

TECHNICAL FIELD

The present invention relates to a PTGS suppressor protein binding inhibitor and an antiviral agent having a novel mechanism of action.

BACKGROUND ART

A very large number of pathogenic viruses have spread on earth, and their infection has caused suffering or economic losses in various organisms such as animals including humans and useful plants (e.g., crops). Examples of viral diseases caused by a pathogenic virus infection include rice dwarf disease caused by rice dwarf virus infection, tomato mosaic disease caused by tobacco mosaic virus infection, human influenza caused by influenza virus infection, human hepatitis B caused by hepatitis B virus infection, and acquired immune deficiency syndrome caused by human immunodeficiency virus (HIV) infection.

Host organisms such as plants or animals, when infected with pathogenic viruses, develop various biological defense mechanisms against the infection to inhibit the growth of the viruses or to relieve the disease symptom. One of these defense mechanisms is post-transcriptional gene silencing (hereinafter, abbreviated to PTGS). PTGS is a phenomenon induced by double-stranded RNAs (dsRNAs) of viruses or the like, wherein transcribed messenger RNAs (mRNAs) are degraded in a sequence-specific manner. PTGS is a mechanism conserved not only in higher organisms such as plants or animals but also in various other organism species from protozoans to fungi and is thought to be a particularly important defense mechanism for plants which do not have an immune system, unlike animals. Specifically, in this mechanism, PTGS-inducing dsRNAs are degraded by intracellular nuclease Dicer or an enzyme analogous thereto into short RNAs of approximately 21 to 24 bases called small interfering RNAs (siRNAs), and the siRNA is further incorporated into a nuclease complex called an RNA-induced silencing complex (RISC), which in turn cleaves mRNA homologous to the siRNA sequence, thereby inhibiting the expression of the target protein such as viruses.

It has recently been revealed that many pathogenic viruses encode, as a counter against the PTGS mechanism of host organisms, a suppressor protein that inhibits this PTGS (PTGS suppressor protein; hereinafter, abbreviated to PTGS-SP) (e.g., Patent Document 1). It has further been reported that the majority of these PTGS-SPs inhibit PTGS through the direct binding to siRNAs (e.g., Non-Patent Document 1).

PTGS-SPs expressed by plant viruses have been reported, for example, HC-Pro of viruses of the genus Potyvirus (see Non-Patent Document 2), 2b of viruses of the genus Cucumovirus (see Non-Patent Document 3), p25 of viruses of the genus Potexvirus (see Non-Patent Document 4), p19 of viruses of the genus Tombusvirus (see Non-Patent Document 5), and coat proteins of viruses of the genus Carmovirus (see Non-Patent Document 6).

Many attempts have been made to develop preventive or therapeutic agents for the viral diseases for reducing damages caused by the viral diseases. For example, M2 ion-channel inhibitors (e.g., amantadine) and neuraminidase inhibitors (e.g., zanamivir phosphate and oseltamivir) are known as effective therapeutic agents for influenza. These M2 ion-channel and neuraminidase inhibitors probably exert therapeutic effects on influenza by preventing the influenza viruses from growing or infecting other cells. Moreover, known effective therapeutic agents for acquired immune deficiency syndrome are broadly classified into reverse transcriptase inhibitors (e.g., azidothymidine and didanosine) and protease inhibitors (e.g., ritonavir and indinavir). Multi-drug therapy using these agents exerts remarkable effects, which drastically reduces the number of deaths in advanced countries.

However, these therapeutic agents for influenza or acquired immune deficiency syndrome are also known to have side effects, and it is believed that drug resistance viruses will inevitably appear due to the variability of the viruses. Therefore, the development of a novel antiviral agent having a different mechanism of action has been demanded. Furthermore, agents against viruses, except for some agents structurally similar to nucleic acids, are only applicable to a target viral disease. Moreover, vaccination, albeit effective, must be performed before infection and has problems such as time taken to develop antibodies or the easily variable antigenic site of viruses. Furthermore, the therapeutic agents or vaccines are only applicable to a target viral disease. Therefore, therapeutic agents for viral diseases had to be developed for each type of virus.

On the other hand, various control methods have been developed for viral diseases in plants. Examples thereof include selective breeding of resistant varieties to viral diseases, raising of virus-free plants by stem tip culture or heat treatment, inhibition of pathogenic virus infection by treatment with selected attenuated viruses, and use of plants having virus resistance imparted by transformation. Moreover, examples of the control methods using agricultural chemicals include use of a fungicide that induces the resistance of plants or an insecticide that targets insect vectors or the like for viruses.

However, the breeding of resistant varieties requires a long period, and resistant strains of viruses inevitably appear. The raising of virus-free plants by stem tip culture or the like is not perfect. The use of attenuated viruses is highly effective for viral disease control. However, attenuated viruses are difficult to stably prepare and are effective only for viruses of the same species or related species. Plant defense activators have unstable effects. Spraying large amounts of insecticide that preventively controls insect vectors for viruses may lead to environmental pollution and cannot be expected to have therapeutic effects on virus-infected plants.

On the other hand, urgency and markets for antiviral agents for viral diseases in plants are much smaller than those for antiviral agents for viral diseases in humans. Therefore, it is highly possible that the cost of developing the antiviral agents for viral diseases in plants cannot be recovered even if they are developed at cost much lower than the cost of developing the antiviral agents for viral diseases in humans, for example, anti-HIV drugs or anti-influenza drugs. In addition, the existing vaccines or antiviral agents are expected, as described above, to be effective only for the target viruses, and resistant strains of viruses inevitably appear. Therefore, the development of antiviral agents for viral diseases in plants has hardly proceeded so far.

  • Patent Document 1: Japanese Laid-Open Patent Application No. 2004-344110
  • Non-Patent Document 1: Goto K., et al., Plant Cell Physiol. 2007, 48, 1050-60
  • Non-Patent Document 2: Anandalakshmi R., et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 13079-13084
  • Non-Patent Document 3: Brigneti G., et al., EMBO J., 1998, 17, 6739-6746
  • Non-Patent Document 4: Voinnet O., et al., Cell, 2000, 103, 157-167
  • Non-Patent Document 5: Baulcombe D C., et al., Trends Biochem Sci. 2004, 29, 279-81
  • Non-Patent Document 6: Qu F., et al., J. Virol. 2003, 77, 511-522

DISCLOSURE OF THE INVENTION Object to be Solved by the Invention

It has been demanded to provide a control method which has a mechanism of action different from conventional one as a substitute for the existing viral disease control methods described above and is used in more practical and safer manners. Thus, an object of the present invention is to provide a viral disease control agent having a mechanism of action different from conventional one.

Means to Solve the Object

The present inventors have conducted diligent studies in consideration of the object and consequently found that a therapeutic effect of reducing damages caused by viral diseases or an effect of attenuating highly virulent viruses having strong pathogenicity is obtained without toxicity to or strong influence on applicable organisms by inhibiting the binding of PTGS-SP to siRNA such that the PTGS-SP function is inhibited. Furthermore, the present inventors have actually studied the effects of compounds that actually inhibit the functions of various PTGS-SPs. Based on these findings, the present invention has been completed.

Specifically, the present invention relates to:

[1] a PTGS suppressor protein binding inhibitor containing a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein;

[2] the PTGS suppressor protein binding inhibitor according to [1], wherein the substance α is siRNA; and

[3] the PTGS suppressor protein binding inhibitor according to [1] or [2], wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):

Moreover, the present invention relates to:

[4] the PTGS suppressor protein binding inhibitor according to [1] or [2], wherein the compound is a reaction product of croconic acid with hydrogen peroxide;

[5] an antiviral agent comprising as an active ingredient a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein;

[6] the antiviral agent according to [5], wherein the substance α is siRNA; and

[7] the antiviral agent according to [5] or [6], wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):

Furthermore, the present invention relates to:

[8] the antiviral agent according to [5] or [6], wherein the compound is a reaction product of croconic acid with hydrogen peroxide.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 It is a graph showing the inhibitory activity of compound 7 of the present invention on CMV 2b according to a protoplast method.

FIG. 2 It is a photograph showing the inhibitory activity of compound 7 of the present invention on CMV 2b according to a silencing plant method.

FIG. 3 It is a graph showing the antiviral activity of compound 7 of the present invention according to a symptom test method.

BEST MODE OF CARRYING OUT THE INVENTION

A PTGS-SP binding inhibitor of the present invention is characterized by containing a compound having inhibitory activity on the binding of PTGS-SP to a substance α (hereinafter, also referred to as a “compound according to the present invention”), wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS-SP and shows a decrease in the property of inducing PTGS upon binding to the PTGS-SP. The inhibition of the binding of a substance α to PTGS-SP can restore the substance α function inhibited by PTGS-SP, i.e., the function of inducing PTGS. Therefore, the use of the compound according to the present invention can reduce the inhibitory effect of viruses on PTGS, resulting in, for example, the reduced toxicity or inhibited growth of the viruses. As a result, an antiviral effect is obtained.

(PTGS-SP Protein)

The PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention is not particularly limited as long as it is a protein that is derived from any kind of virus and has the ability to inhibit the PTGS of one or more organisms. Preferable examples of the organisms can include plants and animals. The plants can be exemplified more preferably by: food crops such as cereals (e.g., rice, wheat, and corn), pulse crops (e.g., soybean and peanut), tubers (e.g., potato and sweet potato), vegetables (e.g., Japanese radish, carrot, cabbage, lettuce, eggplant, cucumber, and tomato), and fruit trees (e.g., apple, pear, and citrus); and nonfood crops such as flowers and ornamental plants (e.g., rose, carnation, and chrysanthemum), foliage plants (e.g., ivy and maidenhair), and trees (e.g., pine and cherry). More preferable examples of the animals can include birds and mammals such as human, monkey, chimpanzee, cow, horse, pig, sheep, rabbit, dog, cat, rat, mouse, and guinea pig.

Specifically, the PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention can be exemplified preferably by: PTGS-SPs derived from viruses whose natural host is a plant, such as HC-Pro of viruses of the genus Potyvirus (e.g., TuMV: turnip mosaic virus), 2b of viruses of the genus Cucumovirus (e.g., CMV: cucumber mosaic virus), p25 of viruses of the genus Potexvirus (e.g., PVX: potato virus X), p19 of viruses of the genus Tombusvirus (e.g., TBSV: tomato bushy stunt virus), and coat proteins of viruses of the genus Carmovirus (e.g., CarMV: carnation mottle virus); and PTGS-SPs derived from viruses whose natural host is an animal (particularly, a mammal), such as tat (Genbank Accession No. NC001802 or NC 001722) of viruses of the genus Lentivirus (e.g., HIV: human immunodeficiency virus), NS1 (Genbank Accession No. NC 002020) of viruses of the genus Influenzavirus A (e.g., FLUAV: influenza A virus), NS1 (Genbank Accession No. NC 002211) of viruses of the genus Influenzavirus B (e.g., FLUBV: influenza B virus), and NS1 of viruses of the genus Influenzavirus C (e.g., FLUCV: influenza C virus).

In addition to the above-exemplified PTGS-SPs known in the art, any protein that functions as PTGS-SP can be targeted by the PTGS-SP binding inhibitor of the present invention.

Whether a certain protein is a PTGS-SP can be confirmed by: for example, artificially inducing PTGS of an arbitrary gene in a cell; causing the cell to express the protein simultaneously with a protein encoded by the arbitrary gene; and examining the recovery of the arbitrary gene from PTGS, compared with the cell not expressing the protein. The decrease in PTGS can be confirmed by detecting a decrease in the accumulation level of mRNAs of the gene targeted by PTGS or a decrease in the accumulation level of its target protein itself.

For example, whether a certain protein is a PTGS-SP can be confirmed by an agroinfiltration method which involves: injecting a GFP (green fluorescence protein) gene into the intercellular space of a plant leaf using Agrobacterium; and transiently inducing PTGS of the GFP gene. A virus gene encoding a PTGS-SP candidate is expressed simultaneously with the GFP gene, and the protein encoded by this virus gene is identified as PTGS-SP when light emitted by GFP is observed. Alternatively, it can also be confirmed by a protoplast method which involves transiently inducing PTGS of the GFP gene using the protoplast of a plant leaf. In this case, the GFP gene and so on are directly incorporated into the protoplast by polyethylene glycol (PEG), and PTGS-SP can be identified based on the presence or absence of light emitted by GFP.

(Substance α)

The substance α according to the present invention is not particularly limited as long as it is a substance that has property of binding to any PTGS-SP and property of inducing PTGS in the cell of any organism and shows a decrease in its own property of inducing PTGS upon binding to the PTGS-SP. The substance α is preferably a nucleic acid, more preferably virus-derived RNA (e.g., dsRNA or siRNA), and even more preferably siRNA. Specifically, the RNA used as the substance α can be exemplified by a virus-derived RNA sequence or a portion thereof and can be exemplified more preferably by virus-derived siRNA of 21 to 23 bases.

The sequence of the dsRNA or siRNA used as the substance α according to the present invention is not particularly limited and is preferably a sequence (or a partial sequence thereof) corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid, more preferably a sequence of 20 to 27 bases corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid, and even more preferably a sequence of 21 to 23 bases corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid.

Whether the substance α such as dsRNA or siRNA binds to PTGS-SP can be confirmed by using a method described later such as surface plasmon resonance, single-molecule fluorescence analysis, gel shift assay, and thermal denaturation. Moreover, whether the substance α such as dsRNA or siRNA shows a decrease in its property of inducing PTGS upon binding to the PTGS-SP can be confirmed by: artificially inducing PTGS of an arbitrary gene in a cell; causing the cell to express PTGS-SP; and examining the promotion of the intracellular PTGS in the presence of the particular substance, compared with the absence of the substance.

(Inhibitor of the Present Invention)

The compound used as the inhibitor according to the present invention is not particularly limited as long as it has inhibitory activity on the binding of a substance a to PTGS-SP. The compound according to the present invention also includes compounds such as proteins (e.g., antibodies) and nucleic acids. Specifically, the compound according to the present invention can be exemplified preferably by compounds shown in Table 1 below or derivatives thereof.

These compounds are cyclic ketone compounds. The compounds of compound Nos. 7 and 8 are reaction products of croconic acid with hydrogen peroxide, synthesized in Synthesis Examples 1 and 2, respectively. The compound according to the present invention other than the compounds shown in Table 1 can be identified easily by screening using an evaluation system of the present invention (in vitro and in vivo screening methods) described later.

TABLE 1 Compound No. Structural formula 1 2 3 4 5 6 7 Compound of Synthesis Example 1 8 Compound of Synthesis Example 2 9 10 11 12 13 14 15 16 17 18 19 20

Of these compounds, the compounds of compound Nos. 5, 6, 7, 8, 12, 13, 14, and 20 are preferred.

Of the compounds of above Table 1, compound Nos. 7 and 8 are novel compounds, and the compounds other than compound Nos. 7 and 8 are commercially available.

These compounds or derivatives thereof can be synthesized by performing a reaction known in the art with appropriate compounds as raw material compounds.

Particularly, the above compound Nos. 7 and 8 can be synthesized by, for example, methods specifically described later in Examples.

The PTGS-SP binding inhibitor of the present invention may contain only one of the compounds according to the present invention or may contain two or more thereof.

(Antiviral Agent of the Present Invention)

An antiviral agent of the present invention is characterized by comprising the compound of the present invention as an active ingredient. The use of the antiviral agent of the present invention can restore the substance α function inhibited by PTGS-SP, i.e., the function of inducing PTGS. Based on such a mechanism of action, the antiviral agent of the present invention can reduce the inhibition of PTGS caused by highly virulent viruses, resulting in, for example, the inhibited growth or reduced toxicity of the viruses. As a result, the antiviral agent of the present invention exerts an antiviral effect.

The antiviral agent of the present invention may contain only one of the compounds according to the present invention as an active ingredient or may contain two or more thereof as active ingredients. Moreover, it is preferred from the viewpoint of obtaining a more excellent antiviral agent that the antiviral agent of the present invention should further contain a substance that promotes the general resistance of organisms to viruses unless the PTGS-SP binding inhibitory activity of the compound according to the present invention is inhibited. The substance that promotes the resistance of host organisms to viruses is not particularly limited and can be exemplified preferably by substances that promote the resistance of plants to viruses, such as fungicides known as plant defense activators (e.g., probenazole and tiadinil), or isonicotinic acid, salicylic acid, and ascorbic acid).

The antiviral agent of the present invention may contain optional additional ingredients unless the PTGS-SP binding inhibitory activity of the compound according to the present invention is inhibited. The optional additional ingredients can be exemplified by diluents or excipients such as fillers, expanders, binders, wetting agents, disintegrants, surfactants, and lubricants.

The dosage form of the PTGS-SP binding inhibitor or the antiviral agent of the present invention is not particularly limited and can be selected appropriately from tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.), ointments, inhalants, sprays, and so on according to an applicable organism used. The amount of the PTGS-SP binding inhibitor or the antiviral agent used differs depending on the mode of use, an applicable organism used, the type of the compound of the present invention contained therein, and so on and can however be determined appropriately by those skilled in the art.

A method for using the PTGS-SP binding inhibitor or the antiviral agent of the present invention is not particularly limited and can be determined appropriately by those skilled in the art according to the property of the compound of the present invention contained therein, the type of an applicable organism used, and so on. When the applicable organism used is an animal, the use method can be exemplified preferably by oral administration, intravenous injection, intramuscular injection, transvaginal administration, transdermal application, and inhalation. When the applicable organism used is a plant, the use method can be exemplified preferably by foliage application, dip treatment, injection into soil, seed disinfection, and smoking.

The amount of the PTGS-SP binding inhibitor or the antiviral agent of the present invention used is not particularly limited and can be determined appropriately by those skilled in the art according to the type of an applicable organism used, a use method, and so on. Particularly, when the applicable organism used is an animal, the amount can be selected appropriately according to the age, body weight, and condition of the applicable organism used, an administration method, and so on.

(Screening Method) 1) In Vitro Screening Method

An in vitro screening method for the compound according to the present invention is not particularly limited as long as it is an evaluation method using the degree of inhibition of the binding of a substance α to PTGS-SP as an index or an evaluation method which involves measuring the specific binding to PTGS-SP. Whether or not a test compound inhibits the binding of a substance α to PTGS-SP or the degree of inhibition of the binding can be measured quantitatively and evaluated by using, for example, a known method such as single-molecule fluorescence analysis, surface plasmon resonance, gel shift assay, dual polarization interferometry, photothermal spectroscopy, and quartz crystal microbalance. The single-molecule fluorescence analysis method eliminates the need of sample immobilization and achieves multi-sample treatment under conditions of a solution system close to an in vivo environment. However, this method has the disadvantage that it is susceptible to interference of the autofluorescence of a compound. The surface plasmon resonance method requires sample immobilization and is however not influenced by the autofluorescence of a compound. The gel shift assay method is unsuitable for multi-sample treatment and however has the advantage that it eliminates the need of sample immobilization and is not influenced by the autofluorescence of a compound.

The single-molecule fluorescence analysis method is an approach which involves: detecting a change in the behavior of labeled fluorescent molecules by measuring the number, intensity, or the like of the labeled fluorescent molecules using a confocal laser scanning microscope: and analyzing the intermolecular interaction between two substances. Screening based on the single-molecule fluorescence analysis method can be performed, for example, by applying a sample solution comprising PTGS-SP, a fluorescently labeled substance α, and a test compound to a measurement apparatus for single-molecule fluorescence analysis such as Olympus MF20 to detect a change in the behavior of the labeled substance α.

The surface plasmon resonance method is an apparatus which involves: monitoring a change in refractive index caused by, for example, a change in the weight of molecules immobilized on a thin gold film; and analyzing the intermolecular interaction between two substances. Screening based on the surface plasmon resonance method can be performed, for example, by: immobilizing a substance α onto sensor chip surface; and applying a sample solution comprising PTGS-SP and a test compound to a Biacore measurement apparatus or the like to detect, as a change in the refractive index of the solution, a change in the weight of molecules caused by the binding of the substance α immobilized on the sensor chip to the PTGS-SP.

The gel shift assay method is an approach which involves: mixing two high molecular substances; subjecting the mixture to electrophoresis; and analyzing whether the two substances are bound with each other, from the electrophoretic band positions or concentrations. Screening based on the gel shift assay can be performed, for example, by subjecting a sample solution comprising a labeled substance α, PTGS-SP, and a test compound to polyacrylamide gel electrophoresis using a universal apparatus. The binding of the substance α to the PTGS-SP increases a molecular weight, resulting in slow migration. By contrast, when the binding of the substance α to the PTGS-SP is inhibited by the compound, the migration of the substance α is faster. Therefore, the degree of the binding can be analyzed by comparing these electrophoretic band positions or amounts.

2) In Vivo Screening Method

An in vivo screening method for the compound according to the present invention is not particularly limited as long as it is an evaluation method using the degree of inhibition of the PTGS-SP function as an index. Whether or not a test compound inhibits the PTGS-SP function can be evaluated by, for example, an agroinfiltration method, a protoplast method, a silencing plant method using a change in flower color as an index, or a symptom test method which involves examining the symptom of a viral disease using plant seedlings.

The agroinfiltration method is a method which involves: simultaneously injecting, for example, a GFP gene and a viral PTGS-SP gene into the intercellular space of a plant leaf using Agrobacterium for transient transformation; and conducting evaluation based on the principle that the GFP fluorescence disappears when PTGS functions while the GFP fluorescence is observed when the viral PTGS-SP functions. Furthermore, by treating the plant leaf with a test compound before and after the gene injection, the test compound can be determined to inhibit the PTGS-SP function when the GFP fluorescence disappears.

The protoplast method is a method based on the same principle as that of the agroinfiltration method. Specifically, this method utilizes protoplast instead of the plant leaf and involves: directly incorporating a firefly luciferase gene and a viral PTGS-SP gene into the protoplast by use of polyethylene glycol; and conducting evaluation based on the principle that light emission derived from the luciferase activity disappears when PTGS functions while stronger light emission is observed when the viral PTGS-SP functions. By treating the protoplast with a test compound, the test compound can be determined to inhibit the PTGS-SP function when light emission derived from the luciferase activity is significantly decreased, compared with untreated protoplast.

The silencing plant method is a method which utilizes the principle that a variety whose flower color is wholly or partially white shows a change in the flower color when infected with a plant virus having PTGS-SP. Specifically, this method utilizes the fact that the expression of pigment genes is inhibited by natural PTGS in many white flowers. The inhibition of pigment expression by PTGS is canceled by the virus infection such that the pigment gene is expressed. As a result, the flower exhibits a red or blue color changed from the white color. Here, the flower is treated with a compound, and the inhibitory effect of the compound can be determined based on a white flower color recovered by the inhibition of the viral PTGS-SP function.

The symptom test method using plant seedlings is a method which involves observing the symptom of a viral disease to determine the antiviral effect of a compound. Specifically, in this method, the plant seedlings are treated with a compound before and after inoculation of a plant virus whose infection causes a severe symptom in the plants, and the antiviral effect is determined based on the severity of the symptom.

3) Methods for Preparing PTGS-SP and Substance α for Screening

The PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention can be obtained using a universal approach, for example, PCR based on sequence information of the GenBank Accession No. described above.

The PTGS-SP can be expressed in, for example, an expression system using E. coli, yeast, or insect cells or a cell-free protein synthesis system derived from wheat germs or rabbit reticulocytes.

When E. coli is used, a tag sequence is added to a sequence encoding the PTGS-SP of interest, and the sequence is inserted into an arbitrary vector for E. coli expression, with which an arbitrary E. coli strain can then be transformed to express the PTGS-SP. Then, it is preferred that the PTGS-SP is purified according to a standard method based on the type of the added tag. The PTGS-SP can be purified easily by adding, for example, His-tag for TBSV p19; or MBP (maltose-binding protein) for TAV (tomato aspermy virus) 2b (TAV 2b) or HIV tat, and can be used without troubles in the evaluation system.

In the present invention, instead of the PTGS-SP, a synthetic peptide having a partial structure thereof can also be used in the evaluation system. The synthetic peptide can be obtained as a peptide of 20 to 40 bases comprising the portion of two or more primarily consecutive or adjacent strongly basic amino acids (arginines or lysines) using a usual approach, for example, solid-phase synthesis using an Fmoc or Boc method based on the sequence information of the PTGS-SP.

In the present invention, instead of the PTGS-SP, even a length or sequence variant of a synthetic peptide having a partial structure thereof can also be used in the evaluation system of siRNA binding inhibition. The variant peptide used in the siRNA binding test must have a sequence of three or more primarily consecutive or adjacent strongly basic amino acids (arginines or lysines). For example, for HIV tat, consecutive arginines or lysines starting at N-terminal position 49 are important, and its ability to bind to siRNA is decreased by converting even one of arginines 52, 53, and 55 to a neutral amino acid leucine and the ability is lost by converting two or more thereof to leucine. The ability to bind to siRNA is maintained even if all of these arginines are converted to another strongly basic amino acid lysine. On the other hand, the ability to bind to siRNA is maintained even if independently located arginine such as arginine 78 is converted to a neutral amino acid leucine.

Moreover, the nucleic acid as the substance α, such as dsRNA or siRNA, can be obtained using a universal approach, for example, PCR.

EXAMPLES

Hereinafter, the present invention will be described more specifically with reference to Examples. However, the technical scope of the present invention is not intended to be limited to these Examples.

(Synthesis of Compound) Synthesis Example 1 Preparation of compound 7

3.0 g of croconic acid was dissolved in 30 ml of pure water. To the solution, 1.2 g of a 30% hydrogen peroxide solution was added at room temperature, and the reaction solution was stirred at 20 to 30° C. for 3 days. The reaction solution was concentrated under reduced pressure to obtain 2.6 g of a compound 7. 13C-NMR (D2O) δ 178.6, 129.5, 75.7.

Synthesis Example 2 Preparation of Compound 8

5.0 g of croconic acid was dissolved in 50 ml of pure water. To the solution, 2.0 g of a 30% hydrogen peroxide solution was added at room temperature, and the reaction solution was stirred at 100° C. for 24 hours. The reaction solution was concentrated under reduced pressure to obtain 3.3 g of a compound 8. 13C-NMR (D2O) δ 195.3, 193.9, 180.5, 178.7, 176.7, 161.7, 151.3, 150.0, 129.7, 75.8, 73.1, 72.5, 59.9, 45.9, 39.8.

(Compound Screening)

1. Preparation of Biotinylated siRNA

Single-stranded RNA (sense strand: SEQ ID NO: 1) consisting of 21 bases was prepared, and this sequence was 3′-terminally biotinylated. Next, single-stranded RNA (antisense strand: SEQ ID NO: 2) consisting of 21 bases complementary to this sense strand was annealed thereto. This annealing product was purified to prepare biotinylated siRNA of 21 base pairs.

2 Preparation of PTGS-SP 1) Preparation of TBSV-p19

The PTGS-SP p19 (Genbank Accession No. NC001554) of TBSV used in screening was expressed and purified as follows: constructs comprising a p19 gene and a flag-tag sequence ligated to a vector pCold I DNA (TAKARA BIO INC.) for cold shock expression were prepared, and E. coli BL21 strains were transformed with the constructs. The strains were cultured at 15° C. for 24 hours in the presence of 0.1 mM IPTG to induce the expression. The strains were collected and homogenized. After centrifugation, the supernatant was subjected to extraction using a vector-derived His-tag and an Ni-NTA column with 200 mM to 500 mM imidazole. The expressed p19 was confirmed using anti-flag antibodies. The p19 in the extraction fraction was purified.

2) Preparation of TAV-2b

The 2b (Genbank Accession No. NC003838) of TAV used in screening was expressed and purified as follows: constructs pMAL-TAV2b-flag comprising a TAV-2b gene and a flag-tag sequence ligated to a vector pMAL-c2X (BioLabs Inc.) were prepared, and E. coli strains JM109 were transformed with the constructs and cultured in an LB/Amp medium at 37° C. The expression was induced for 2 hours in the presence of 0.3 mM IPTG. After centrifugation, the strains were washed and resuspended in a buffer solution. These strains were homogenized using a homogenizer. After centrifugation, the supernatant fraction was applied to an amylose-lysine column, and elution with 10 mM maltose was performed to obtain MBP-fused TAV-2b. The expressed MBP-TAV2b-flag was confirmed by SDS-PAGE and then cleaved using Factor Xa to separate between MBP and TAV2b-flag.

The TAV2b-flag fraction was obtained by purification using a flag column.

3) Preparation of Synthetic Peptide

A peptide (SEQ ID NO: 3) comprising the portion of a few consecutive or adjacent strongly basic amino acids (arginines) contained in HIV tat was designed as a synthetic peptide having a partial structure of the PTGS-SP based on the sequence information of the PTGS-SP. The actual synthesis was conducted by a contract manufacturer of peptide synthesis (Biologica Co., Ltd.) to obtain a peptide having 98% purity.

3 Screening 1) Surface Plasmon Resonance Method

An apparatus Biacore X (manufactured by Biacore) was used. A solution of the 3′-terminally biotinylated siRNA (10 μg/ml) of 21 base pairs was injected at a rate of 5 μl/min to a sensor chip SA modified with streptavidin to immobilize the siRNA on the sensor chip. A test compound used in screening was dissolved in dimethylformamide (DMF) or water such that it was adjusted to 25 ppm in terms of the final compound concentration. The PTGS-SP p19 or TAV-2b wad dissolved in a buffer solution for Biacore (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA) such that it was adjusted to approximately 10 μg/ml in terms of the final concentration. The test compound was mixed with the PTGS-SP. After centrifugation, bovine serum albumin was added to the supernatant, and the mixture was dialyzed at 4° C. for 2 hours using a dialysis membrane (manufactured by PIERCE, 7000MWCO) and then adjusted to the concentrations described above to obtain a sample solution of the test compound. The Biacore X apparatus was operated according to the manual to measure the influence of the test compound on the binding of the siRNA immobilized on the sensor chip to the PTGS-SP. The binding inhibition rate of the test compound was calculated with non-biotinylated free siRNA (final concentration: 0.1 μM) as a positive control when an inhibition rate obtained without the compound addition is defined as 0% and an inhibition rate obtained using the positive control is defined as 100%. The binding inhibitory activity of the compound of the present invention on the p19 or TAV-2b is shown in Table 2.

2) Gel Shift Assay Method

A test compound used in screening was dissolved in dimethylformamide (DMF) or water such that it was adjusted to 100 ppm in terms of the final compound concentration. A gel shift assay kit (LightShift Chemiluminescent EMSA Kit manufactured by Pierce) was used. The synthetic peptide of tat (500 nM) and the test compound solution were mixed into a buffer solution supplemented with 0.005% BSA, and the mixture was shaken at 25° C. for 30 minutes. Then, the biotinylated siRNA (500 μM) was mixed therewith, and the mixture was further shaken at 25° C. for 30 minutes. Each sample was electrophoresed on a 5% polyacrylamide gel and then transferred to a nylon membrane for 1 hour. The membrane was blocked and then treated with peroxidase-conjugated streptavidin. A luminol-peroxide substrate solution was added thereto for reaction, and the membrane was covered with an X-ray film and exposed to light for approximately 2 minutes. The binding inhibition rate of the test compound was calculated from the band positions and concentrations of the electrophoresed free biotinylated siRNA or the electrophoresed biotinylated siRNA bound with the synthetic peptide. The binding inhibitory activity of the compound of the present invention on the synthetic peptide of tat is shown in Table 2.

TABLE 2 Binding inhibition rate (%) Gel Biacore shift Compound p19 TAV2b tat 100 No. Structural formula 25 ppm 25 ppm ppm 1 80 80 10 2 75 0 3 0 90 4 20 90 5 100 100 100 6 100 100 100 7 Compound of 100 100 100 Synthesis Example 1 Compound of 100 100 100 8 Synthesis Example 2 9 95 0 0 10 70 50 11 70 20 12 100 95 100 13 100 14 100 15 95 100 80 16 80 0 0 17 100 90 18 90 80 0 19 90 50 0 20 100 80 100

3) Protoplast Method

The leaf abaxial epidermis of tobacco (Nicotiana benthamiana) seedlings was stripped off and left standing at 25° C. for approximately 6 hours in an enzyme solution (2% cellulase RS, 0.5% macerozyme R10, 0.5 M mannitol). This solution was subjected to filtration through two-piece gauze, and mannitol (0.4 M) addition and centrifugation (300 rpm, 2 min) were repeated three times to obtain protoplast. This protoplast was transfected by a PEG method with the following four nucleic acids: an expression plasmid for firefly luciferase (Fluc) as a reporter gene, an expression plasmid for Renilla luciferase (Rluc) as an internal standard, dsRNA of firefly luciferase (Fluc) for inducing silencing, and a PTGS-SP CMV 2b gene. The protoplast was cultured for approximately 24 hours and then homogenized. The expression level of each Fluc or Rluc protein intracellularly expressed was measured as light emission. A test compound was added at the predetermined concentration before the culture, and its inhibitory activity was determined based on the Fluc/Rluc ratio in the presence or absence of the compound.

The inhibitory activity of the compound 7 of the present invention on the CMV-2b is shown in FIG. 1. The ordinate represents the emission intensity of the firefly luciferase reporter gene. The emission intensity was decreased in a manner dependent on the concentration of the compound 7.

4) Silencing Plant Method

A petunia variety was used whose pigment gene expression was inhibited by natural PTGS such that the flower had a white star pattern. This petunia was inoculated and infected with a CMV-L line to prepare a virus disease-affected petunia with completely inhibited natural PTGS, which was then used as a test plant for the PTGS-SP function. To eliminate individual difference, the number of the disease-affected petunia was increased by cuttings, which were then used in the inhibition test. A test compound used in screening was dissolved in dimethylformamide (DMF) or water and adjusted with an MES buffer solution to pH of 5.5 to 6.0 (final concentration: 100 to 1000 ppm). The solution of the compound of the present invention was injected into soil around the test plant, and a change in the flower color of the petunia starting to flower after 1 to 2 weeks was observed to determine the inhibitory activity of the compound on the PTGS-SP function, based on the recovery of the white star pattern.

The inhibitory activity of the compound 7 of the present invention on the CMV-2b is shown in FIG. 2.

The CMV-infected petunia flower (upper box of FIG. 2) had no detectable white star pattern, whereas the flower underwent the injection of the compound 7 of the present invention into soil (middle box of FIG. 2) recovered a white star pattern as in a healthy flower (lower box of FIG. 2).

5) Symptom Test Method

A compound solution diluted to the predetermined concentration was gently injected with a syringe into the abaxial leaf epidermis of tobacco (Nicotiana benthamiana) seedlings. A dry leaf infected with a virus (TAV) was ground with a 10-fold volume of a 0.1 M phosphate buffer solution (pH 7.0) to prepare a crude sap, which was then used as an inoculation sap and wound-applied using Carborundum to the surface of the tobacco leaf to which the compound was injected. After the inoculation, the symptom of the viral disease was observed to determine the antiviral activity of the compound.

The antiviral activity of the compound 7 of the present invention is shown in FIG. 3. The progression of the symptom in the tobacco treated with the compound 7 of the present invention was slower than that in untreated tobacco, demonstrating the inhibition of pathogenesis.

INDUSTRIAL APPLICABILITY

A PTGS-SP binding inhibitor of the present invention can inhibit the binding of PTGS-SP produced by a virus to a substance α such that the PTGS-SP function is decreased, wherein the substance α has the property of inducing PTGS and the property of binding to the PTGS-SP and shows a decrease in the property of inducing PTGS upon binding to the PTGS-SP. The PTGS-SP binding inhibitor of the present invention can decrease the PTGS inhibitory effect involving the PTGS-SP and thereby restore the original action of PTGS, resulting in the inhibited growth or reduced toxicity of the virus that has infected organisms. Therefore, the PTGS-SP binding inhibitor of the present invention can be used as an antiviral agent. The antiviral agent of the present invention has a different mechanism of action from that of known antiviral agents and is therefore expected to be sufficiently effective for, for example, viruses resistant to known antiviral agents.

Moreover, the antiviral agent of the present invention inhibits the binding of PTGS-SP to siRNA such that the PTGS-SP function is inhibited. The antiviral agent of the present invention acts on the functions of PTGS-SPs carried in common by many pathogenic viruses and is therefore expected to be effective for a wider range of viruses. Specifically, X-ray crystallography or the like has revealed that many PTGS-SPs bind, at a site called a nucleic acid-binding region, to siRNA (Non-Patent Document 5). It was demonstrated that the PTGS-SPs bind thereto particularly at a site where two or more strongly basic amino acids (arginines or lysines) are consecutive or adjacent in a primary sequence or three-dimensional positional relationship. The presence of the site of PTGS-SP having such strongly basic amino acids with a high frequency is the condition necessary to bind to siRNA and is a common characteristic of the PTGS-SPs carried by pathogenic viruses. Therefore, the antiviral agent of the present invention is expected to be effective for a wide range of viruses.

The antiviral agent of the present invention, when used in animals, produces therapeutic effects on viral diseases caused by pathogenic viruses. Further, the antiviral agent of the present invention, when used in plants, can reduce severe damage caused by viral diseases and significantly improve the commercial value and productivity of crops.

1. A PTGS suppressor protein binding inhibitor containing a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein. 2. The PTGS suppressor protein binding inhibitor according to claim 1, wherein the substance α is siRNA. 3. The PTGS suppressor protein binding inhibitor according to claim 1, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6): 4. The PTGS suppressor protein binding inhibitor according to claim 1, wherein the compound is a reaction product of croconic acid with hydrogen peroxide. 5. An antiviral agent comprising, as an active ingredient, a compound having inhibitory activity on the binding of a substance α to a PTGS suppressor protein, wherein the substance α has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein. 6. The antiviral agent according to claim 5, wherein the substance α is siRNA. 7. The antiviral agent according to claim 5, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6): 8. The antiviral agent according to claim 5, wherein the compound is a reaction product of croconic acid with hydrogen peroxide. 9. The PTGS suppressor protein binding inhibitor according to claim 2, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6): 10. The PTGS suppressor protein binding inhibitor according to claim 2, wherein the compound is a reaction product of croconic acid with hydrogen peroxide. 11. The antiviral agent according to claim 6, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6): 12. The antiviral agent according to claim 6, wherein the compound is a reaction product of croconic acid with hydrogen peroxide.


Download full PDF for full patent description/claims.

Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this Antiviral agent patent application.
###
monitor keywords



Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Antiviral agent or other areas of interest.
###


Previous Patent Application:
Low temperature enzyme and method thereof
Next Patent Application:
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
Industry Class:
Organic compounds -- part of the class 532-570 series
Thank you for viewing the Antiviral agent patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 0.48952 seconds


Other interesting Freshpatents.com categories:
Electronics: Semiconductor Audio Illumination Connectors Crypto

###

Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. FreshPatents.com Terms/Support
-g2-0.1718
     SHARE
  
           

FreshNews promo


stats Patent Info
Application #
US 20100216981 A1
Publish Date
08/26/2010
Document #
File Date
10/24/2014
USPTO Class
Other USPTO Classes
International Class
/
Drawings
0



Follow us on Twitter
twitter icon@FreshPatents